Table 2

Changes in levels and trends of and absolute and relative changes in medication cost per DDD, procurement volume and spending, for 2017 price-negotiated and comparison group medications

2017 negotiation medications2017 price-negotiated medicationsComparison group medicationsChange relative to comparison group
CoefficientP value95% CICoefficientP value95% CICoefficientP value95% CI
Cost per DDD (US$/DDD)*
Baseline level215.580.000204.37 to 226.80274.830.000267.18 to 282.48−59.160.000−68.55 to −49.77
Baseline trend−2.240.000−3.11 to −1.37−1.710.000−2.35 to −1.07−0.290.463−1.08 to 0.50
Level change after intervention−71.210.000−81.56 to −60.851.540.801−10.81 to 13.89−87.690.000−102.76 to −72.61
Trend change after intervention−0.950.316−2.85 to 0.95−0.240.723−1.63 to 1.14−0.050.951−1.75 to 1.64
Absolute change at 6 months after intervention−76.910.000−90.25 to −63.570.080.989−11.60 to 11.76−88.000.000−102.32 to −73.68
Relative change at 6 months after intervention−48.880.00053.71 to 44.040.040.9894.82 to 4.89−32.940.000−36.24 to −29.64
Absolute change by end of observation period−83.560.000−107.86 to −59.27−1.620.848−18.70 to 15.47−88.360.000−109.37 to −67.36
Relative change by end of observation period−58.990.00069.05 to 48.92−0.740.8468.19 to 6.71−33.330.000−38.55 to −28.11
Volume (no of DDDs)*
Baseline level23.690.00020.01 to 27.378.760.0007.83 to 9.7014.920.00011.21 to 18.64
Baseline trend0.860.0000.55 to 1.170.220.0000.14 to 0.300.640.0000.33 to 0.95
Level change after intervention9.380.0033.45 to 15.31−1.110.143−2.62 to 0.4010.490.0014.51 to 16.48
Trend change after intervention4.990.0004.33 to 5.66−0.210.017−0.38 to −0.045.200.0004.53 to 5.88
Absolute change at 6 months after intervention39.350.00033.73 to 44.97−2.360.002−3.79 to −0.9441.720.00036.04 to 47.39
Relative change at 6 months after intervention85.590.00065.26 to 105.93−16.410.000−24.65 to −8.18164.190.00082.47 to 245.92
Absolute change by end of observation period74.310.00066.09 to 82.54−3.830.001−5.92 to −1.7478.140.00069.84 to 86.45
Relative change by end of observation period142.980.000110.18 to 175.78−24.040.000−34.47 to −13.62261.470.000134.94 to 387.99
Spending (US$)*
Baseline level5279.020.0004892.18 to 5665.862408.590.0002199.23 to 2617.962879.150.0002449.58 to 3308.72
Baseline trend97.360.00064.96 to 129.7638.780.00021.25 to 56.3157.750.00221.77 to 93.73
Level change after intervention−2347.960.000−2972.24 to −1723.67−270.610.110−606.29 to 65.07−2061.560.000−2754.26 to −1368.86
Trend change after intervention135.790.00065.81 to 205.77−62.480.002−100.30 to −24.65198.350.000120.66 to 276.05
Absolute change at 6 months after intervention−1533.220.000−2123.59 to −942.85−645.460.000−964.59 to −326.33−871.430.010−1526.98 to −215.87
Relative change at 6 months after intervention−19.630.000−25.72 to −13.54−18.890.000−26.46 to −11.32−22.320.000−34.13 to −10.51
Absolute change by end of observation period−582.680.178−1446.50 to 281.13−1082.790.000−1551.16 to −614.41517.060.285−442.46 to 1476.58
Relative change by end of observation period−6.860.146−16.12 to 2.39−29.360.000−38.99 to −19.7212.000.346−12.98 to 36.98
  • US$ in 2016

  • *Except for relative changes which are expressed in percent.

  • CI, confidence interval; DDD, defined daily doses.